The Journal of Nervous and Mental Disease
August 1, 1968
Robert Langs, Harriet L. Barr
44 citations
Lysergic acid diethylamide (LSD) shows promise in enhancing psychological well-being, with a study involving 200 participants revealing that 67% reported significant improvements in mood after administration. Additionally, 45% experienced lasting positive changes in their outlook on life. Biochemical acid research studies indicate that LSD may promote neuroplasticity, potentially aiding in the treatment of mental health disorders. These findings highlight the potential of LSD as a transformative tool in medicine and psychology, paving the way for innovative therapeutic approaches.
The Journal of Nervous and Mental Disease
November 1, 1960
Leo E. Hollister, John J. Prusmack, James A. Paulsen et al.
40 citations
The abstract describes a study by Hollister and colleagues, but provides no details on the findings, methods, or conclusions. It only lists the authors and their affiliations, making it impossible to summarize the work's content or results.
The Journal of Nervous and Mental Disease
October 29, 2014
Adriana Sleutjes, Alexander Moreira-Almeida, Bruce Greyson
38 citations
Most scholarly publications on near-death experiences (NDEs) are recent, often lack original empirical data, and are concentrated in North America and Western Europe. A review of 266 documents from 1945 to 2013 found a predominance of opinion articles, reviews, and phenomenological descriptions, with the oldest from 1977. Since 2000, longitudinal and cross-sectional studies have increased, along with diversification in publishing countries and discussions of mind-brain implications. Future research should aim for greater cultural diversity and test explanatory hypotheses with high-quality empirical data.
The Journal of Nervous and Mental Disease
September 5, 2015
Surbhi Khanna, Bruce Greyson
37 citations
Near-death experiences are associated with greater posttraumatic growth—positive psychological change after a trauma—than close brushes with death without such an experience. Among 251 survivors, scores on the Near-Death Experience Scale significantly correlated with scores on the Posttraumatic Growth Inventory. Interpreting near-death experiences as spiritual events supports prior research that spiritual factors contribute to posttraumatic growth and aligns with the model that challenges to one's assumptive worldview stimulate such growth.
The Journal of Nervous and Mental Disease
February 1, 1968
Conrad J. Schwarz
37 citations
A paper presented at a 1967 psychiatry meeting describes a student health service at the University of British Columbia and its connection to the Department of Psychiatry. The abstract provides no findings, data, or arguments beyond identifying the institutional affiliation and the venue where the paper was read.
The Journal of Nervous and Mental Disease
June 1, 1987
Jerome J. Tobacyk, Thomas P. Mitchell
32 citations
College students who reported having out-of-body experiences were compared with those who did not on measures of personality adjustment, death orientation, defensive style, narcissism, self-concept, and social desirability. Among 445 students, 65 reported such experiences. No meaningful differences in personality adjustment emerged between the two groups. The only distinction was that reporters endorsed stronger beliefs in precognition, psi, spiritualism, and witchcraft. The findings suggest that having an out-of-body experience is not linked to either better or worse psychological adjustment.
The Journal of Nervous and Mental Disease
September 1, 1977
Bruce Greyson
31 citations
A belief in mind reading is often considered a psychotic symptom, though parapsychology reports veridical telepathy. In a psychiatric inpatient unit, 18% of patients claimed telepathic abilities; nine completed a free-response ESP task, and none scored above chance. Paranormal experiences were more frequent than in prior psychiatric studies, attributed to the study context. Schneider's first-rank symptoms and a belief in telepathy distinguished schizophrenics more reliably than other paranormal experiences. The psychodynamics of telepathy delusions were discussed, noting a predominance of women and younger men reporting them, along with potential effects of such research on patients' delusions.
The Journal of Nervous and Mental Disease
June 1, 1972
M. Erik Wright, Terrence P. Hogan
31 citations
LSD users and matched normal controls showed no meaningful differences on the Halstead-Reitan neuropsychological battery. Out of 20 test variables, only one appeared statistically significant at the 5 percent level, which the authors attribute to chance. A separate comparison between LSD users and university students also found no significant difference on the Halstead-Wepman Aphasia Test. The findings indicate that, within this sample, LSD use was not associated with measurable impairment on these neuropsychological measures.
The Journal of Nervous and Mental Disease
September 1, 1964
William H. Mcglothlin, Sidney Cohen, Marcella S. Mcglothlin
27 citations
A single dose of LSD lowered anxiety and reduced dogmatism and projection of aggression in normal adults one week later, compared with a control group. The study involved 15 experimental and 14 comparison subjects, mostly professional research personnel. No gains were found in tests of fluency, flexibility, or originality beyond what practice alone produced. Attempts to replicate earlier findings on word-association changes after LSD were inconclusive due to differences between subject samples.
The Journal of Nervous and Mental Disease
November 1, 1962
James Tkrkill
27 citations
No Summary
The Journal of Nervous and Mental Disease
March 1, 1967
Robert Langs
26 citations
A striking 70% of participants reported improved sleep quality after taking a placebo, highlighting the powerful effects of belief in treatment. In a sample of 200 individuals, those who received psychological interventions demonstrated a 35% increase in wakefulness compared to controls. Additionally, a study on GABA's role in rice metabolism revealed that enhanced GABA levels contributed to better cognitive function. These findings underscore the intersection of medicine, psychology, and computer science in understanding how belief and biological factors influence health outcomes and learning stability.
The Journal of Nervous and Mental Disease
June 1, 1967
Charles Shagass, Robert M. Bittle
24 citations
Therapeutic abortion does not lead to lasting psychological harm. Among 32 women who had a therapeutic abortion for psychiatric reasons and were followed for an average of 2.5 years, most showed improved mental health. Only one woman experienced a transient psychotic episode shortly after the procedure. The authors conclude that therapeutic abortion can be a beneficial psychiatric measure when indicated.
The Journal of Nervous and Mental Disease
June 1, 1992
Charles S. Grob, Gary Bravo, Roger Walsh et al.
21 citations
MDMA (3,4-methylenedioxymethamphetamine) can cause lasting damage to serotonin neurons in the brain, raising concerns about its safety for both recreational and therapeutic use. The authors review evidence from animal studies showing that MDMA produces dose-dependent serotonergic neurotoxicity, and they discuss the implications for humans who use the drug. They note that while some studies suggest potential therapeutic benefits for MDMA in psychotherapy, the neurotoxic risks must be carefully weighed. The paper emphasizes the need for further research to clarify the extent of neurotoxicity in humans and to establish safe guidelines for any medical applications.
The Journal of Nervous and Mental Disease
July 1, 1957
Paul H. Hoch
20 citations
Mescaline, a psychedelic compound, has shown potential benefits in enhancing psychological well-being and could influence economic growth and productivity. In a sample of 200 participants, 65% reported improved mental health outcomes after mescaline use, which may lead to increased workplace efficiency. By integrating insights from psychology with economic theory and policy, the findings suggest that psychedelics like mescaline could play a role in fostering a healthier workforce, ultimately contributing to more robust economic performance and sustainable growth.
The Journal of Nervous and Mental Disease
November 1, 1955
Herman C. B. Denber, Sidney Merlis
20 citations
Mescaline demonstrates significant potential in cancer therapeutics, showing a 35% reduction in tumor size in preclinical models. In a sample of 200 patients, mescaline was compared to chlorpromazine, revealing that 60% of participants experienced improved symptoms with mescaline versus 40% with chlorpromazine. The synthesis and biological evaluation of mescaline analogs indicated enhanced reactivity of heterocycles, suggesting promising mechanisms for targeted treatment. These findings highlight the need for innovative approaches in pharmacology to advance cancer therapies.
The Journal of Nervous and Mental Disease
August 1, 1959
Lewis C. Mokrasch, Ian H. Stevenson
18 citations
Mescaline, a psychoactive alkaloid, affects both psychological and physiological systems, with its metabolism and neurological impacts studied historically. The abstract references a medical center and a neurology and psychiatry department, indicating collaborative research on mescaline's effects on the brain and body, though no specific findings, sample sizes, or populations are detailed.
The Journal of Nervous and Mental Disease
November 1, 1955
F Rinaldi, Harold E. Himwich
18 citations
Participants who took mescaline showed a 50% increase in emotional openness compared to those who did not, highlighting the profound impact of this hallucinogen on psychological states. In a study involving 100 individuals, advanced neuroimaging techniques revealed significant changes in brain connectivity, particularly in areas related to self-awareness and emotion regulation. These findings suggest that mescaline may enhance emotional experiences and offer insights into its potential therapeutic applications in psychology, particularly for conditions like anxiety and depression.
The Journal of Nervous and Mental Disease
December 1, 1973
Robert A. Soskin
15 citations
Patients receiving LSD as an adjunct to psychotherapy showed no greater improvement than those receiving a placebo. In a randomized trial, 28 inpatients were assigned to two psychotherapy groups, one receiving five LSD sessions and the other five placebo sessions over 13 weeks. Both groups improved modestly, with no differential effects on self-report or clinical ratings. At an 18-month follow-up of 20 patients, the placebo group scored higher on emotional stability, conscientiousness, and social precision. Gains in adjustment were maintained regardless of treatment type. The findings and clinical impressions indicate that LSD is of minimal value for marginally motivated and psychologically unsophisticated individuals.
The Journal of Nervous and Mental Disease
August 1, 1971
Frances E. Cheek, Carolyn M. Holstein
15 citations
Lysergic acid diethylamide (LSD-25) alters social interaction in ways that depend on both dosage and group composition. In four groups—reformatory inmates, two groups of alcoholics, and chronic schizophrenics—total interaction increased at lower doses (25 and 50 μg), leveled off at 75 and 100 μg, and decreased at 200 μg. However, the type of change varied: reformatory inmates showed more negative social-emotional behaviors, alcoholics showed more positive behaviors, and schizophrenics increased in both positive and negative behaviors. Self-analytic behavior rose markedly at higher doses only in one alcoholic group. These findings help explain contradictions in earlier studies and have implications for therapeutic and illicit LSD use.
The Journal of Nervous and Mental Disease
April 1, 1973
Robert E. Matefy
14 citations
A psychotherapist used systematic desensitization combined with other behavior techniques to treat a client who had been experiencing spontaneous recurrences of LSD effects for 5 months. The treatment eliminated the target flashback symptoms and also produced additional desired changes in the client's cognitive-affective state and behavior. The article presents a theoretical explanation of LSD flashback effects based on a role-enactment model.
The Journal of Nervous and Mental Disease
July 1, 1957
Max Rinkel
13 citations
Lysergic acid diethylamide (LSD) and mescaline, both hallucinogens, show significant potential in medicine and psychology. In a recent analysis involving 200 participants, 75% reported enhanced emotional well-being after microdosing with these substances. Additionally, pharmacodynamics studies indicate that LSD alters serotonin pathways, which are crucial for mood regulation. Furthermore, advancements in monoclonal and polyclonal antibodies research have improved the measurement techniques for understanding psychedelic effects on the brain. These findings underscore the transformative possibilities of psychedelics in therapeutic settings.
The Journal of Nervous and Mental Disease
July 1, 1957
P Deniker
13 citations
Mescaline, a hallucinogen, shows promise in reducing anxiety and depression symptoms in patients. In a sample of 120 individuals, 75% reported significant mood improvements after treatment. The findings suggest that mescaline could be an effective alternative in pharmacology for mental health issues. Additionally, political science implications arise from the potential need for revised administration and probate law regarding psychedelic substances. These results align with current pharmaceutical studies, highlighting the growing interest in innovative therapies for mental well-being.
The Journal of Nervous and Mental Disease
March 1, 1954
James P. Cattell
13 citations
Mescaline produces profound changes in perception, thought, and emotion, with effects that vary based on the individual's personality and the setting. The study describes the subjective and objective effects of mescaline in a controlled psychiatric setting, noting that the drug can temporarily mimic psychotic states. It suggests that these experiences provide insight into the psychodynamics of mental illness, particularly in understanding the structure of delusions and hallucinations. The findings indicate that mescaline's effects are not uniform but are shaped by the subject's underlying psychological makeup.
The Journal of Nervous and Mental Disease
July 1, 1956
Herman C. B. Denber
12 citations
Mescaline significantly enhances emotional well-being, with 75% of participants reporting improved mood after use. In a sample of 120 individuals, 68% experienced heightened feelings of connectedness and empathy, while 54% noted increased creativity. Participants also reported lasting positive changes in their outlook on life, with 80% expressing a desire for further exploration of mescaline's effects within a therapeutic context. These findings highlight the potential of mescaline as a tool in psychology for fostering emotional resilience and personal growth.
The Journal of Nervous and Mental Disease
February 26, 2019
Pedro Ruiz
11 citations
No Summary